Related Experiment Video
Updated: Jul 10, 2026

Isolation of Cancer Stem Cells From Human Prostate Cancer Samples
Published on: March 14, 2014
HLA class II antigen presentation by prostate cancer cells
A R Younger1, S Amria, W A Jeffrey
1Department of Microbiology and Immunology, Medical University of South Carolina, Charleston, SC29425, USA.
Abstract:
Prostate cancer is the second most commonly diagnosed cancer in men. Recent evidence suggests that reduced expression of target protein antigens and human leukocyte antigen (HLA) molecules is the predominant immune escape mechanism of malignant prostate tumor cells. The purpose of this study was to investigate the prospect of antigen specific immunotherapy against prostate cancer via the HLA class II pathway of immune recognition. Here, we show for the first time that prostate cancer cells express HLA class II proteins that are recognized by CD4+ T cells. Prostate tumor cells transduced with class II molecules efficiently presented tumor-associated antigens/peptides to CD4+ T cells. This data suggests that malignant prostate tumors can be targeted via the HLA class II pathway, and that class II-positive tumors could be employed for direct antigen presentation, and CD4+ T-cell mediated tumor immunotherapy.Prostate Cancer and Prostatic Diseases (2008) 11, 334-341; doi:10.1038/sj.pcan.4501021; published online 16 October 2007.
Insights
Prostate cancer cells express human leukocyte antigen (HLA) class II proteins, enabling recognition by CD4+ T cells. This finding supports targeting prostate tumors via the HLA class II pathway for immunotherapy.
Area of Science:
- Oncology
- Immunology
- Cancer Research
Background:
- Prostate cancer is a leading cancer diagnosis in men.
- Malignant prostate tumor cells often evade the immune system by reducing target antigen and human leukocyte antigen (HLA) molecule expression.
- Understanding immune escape mechanisms is crucial for developing effective cancer therapies.
Purpose of the Study:
- To investigate the potential of antigen-specific immunotherapy for prostate cancer.
- To explore the role of the HLA class II pathway in immune recognition of prostate cancer cells.
Main Methods:
- Analysis of HLA class II expression on prostate cancer cells.
- Transduction of prostate tumor cells with class II molecules.
- Assessment of antigen presentation to CD4+ T cells.
Main Results:
- Prostate cancer cells were found to express HLA class II proteins.
- These HLA class II molecules on tumor cells were recognized by CD4+ T cells.
- Transduced prostate tumor cells effectively presented tumor-associated antigens to CD4+ T cells.
Conclusions:
- Prostate tumors can be targeted through the HLA class II pathway.
- HLA class II-positive tumors can be utilized for direct antigen presentation.
- This approach holds promise for CD4+ T-cell mediated tumor immunotherapy in prostate cancer.
Related Concept Videos
Antigens Involved in Adaptive Immunity
Complete Antigens
Complete antigens possess both immunogenicity and reactivity.
Antigen Processing Pathways
MHC Class I: Presenting Endogenous...
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...

